RFS.F

Healthcare Biotechnology

Resverlogix Corp.

€0.05

+0.00 +1.00% today

Price History

Not enough data

Key Stats

Market Cap

17.39M

Avg Volume

EPS

-€0.04

52W High

€0.09

52W Low

€0.05

Div. Yield

0.0%

Valuation

P/B Ratio

-0.21

EV/EBITDA

-22.80

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Assets

(40.3%)

Liquidity & Leverage

Current Ratio

0.04

Quick Ratio

0.03

Total Cash

80,000

Total Debt

91.45M

About

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.